HR and breast cancer: The sensitivities of diagnosing human epidermal growth factor receptor 2 ‐positive (HER2+) breast cancer and triple‐negative breast cancer (TNBC) were 100%, and for the hormone receptor‐positive (HR+)/HER2‐negative (HER2−) subtype, they were 93.1% (Table 1).